Jounce spikes nearly 80% on Gilead plan to buy remaining rights for GS-1811
Check out this evening’s top movers from around Wall Street, compiled by The Fly.
HIGHER
- Jounce Therapeutics (JNCE) up 77.7% after announcing Gilead to buy remaining rights for GS-1811
- Kala Pharmaceuticals (KALA) up 49.7% after announcing FDA accepted application for KPI-012
- Minerva Surgical (UTRS) up 28.6% following $30M private placement of common stock
LOWER
Keywords: Fly Intel, Wall Street, Top Stories, Stocks
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on JNCE:
- Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics
- Gilead to buy remaining rights for GS-1811 from Jounce Therapeutics for $67M
- Jounce Therapeutics presents INNATE Phase 1, SELECT trial data
- Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO – IO) Annual Congress
- Jounce Therapeutics downgraded to Outperform from Strong Buy at Raymond James
